KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Research & Development (2016 - 2025)

Historic Research & Development for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $3.8 billion.

  • Eli Lilly's Research & Development rose 2575.67% to $3.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.3 billion, marking a year-over-year increase of 2134.47%. This contributed to the annual value of $13.3 billion for FY2025, which is 2134.47% up from last year.
  • Latest data reveals that Eli Lilly reported Research & Development of $3.8 billion as of Q4 2025, which was up 2575.67% from $3.5 billion recorded in Q3 2025.
  • Eli Lilly's Research & Development's 5-year high stood at $3.8 billion during Q4 2025, with a 5-year trough of $1.6 billion in Q1 2022.
  • Its 5-year average for Research & Development is $2.4 billion, with a median of $2.4 billion in 2023.
  • In the last 5 years, Eli Lilly's Research & Development plummeted by 370.79% in 2022 and then surged by 3362.36% in 2023.
  • Quarter analysis of 5 years shows Eli Lilly's Research & Development stood at $1.9 billion in 2021, then grew by 5.14% to $2.0 billion in 2022, then increased by 28.38% to $2.6 billion in 2023, then rose by 17.98% to $3.0 billion in 2024, then rose by 25.76% to $3.8 billion in 2025.
  • Its Research & Development was $3.8 billion in Q4 2025, compared to $3.5 billion in Q3 2025 and $3.3 billion in Q2 2025.